PE20120012A1 - Sales de fingolimod - Google Patents
Sales de fingolimodInfo
- Publication number
- PE20120012A1 PE20120012A1 PE2011000987A PE2011000987A PE20120012A1 PE 20120012 A1 PE20120012 A1 PE 20120012A1 PE 2011000987 A PE2011000987 A PE 2011000987A PE 2011000987 A PE2011000987 A PE 2011000987A PE 20120012 A1 PE20120012 A1 PE 20120012A1
- Authority
- PE
- Peru
- Prior art keywords
- salt
- theta
- peaks
- degrees
- approximately
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/122—Propionic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA SAL DE 2-AMINO-2-(2-(4-OCTIL-FENIL)-ETIL)-PROPANO-1,3-DIOL (FTY720) SELECCIONADA DE LAS SALES DE TARTRATO, LACTATO, BENZOATO, SUCCINATO, ENTRE OTROS, DONDE: LA SAL DE TARTRATO ESTA CARACTERIZADA POR UN PATRON DE DIFRACCION EN POLVO DE RAYOS-X CON PICOS A APROXIMADAMENTE 3.1, 19.3, 21.7, 9.6, 17.2, 6.4, 22.6 Y 20.2 GRADOS 2-THETA; LA SAL DE LACTATO ESTA CARACTERIZADA POR UN PATRON DE DIFRACCION EN POLVO DE RAYOS-X CON PICOS A APROXIMADAMENTE 4.3, 8.7, 20.8, 13.1, 10.3, 18.8, 8.1, 21.6, 21.9 Y 19.6 GRADOS 2-THETA; LA SAL DE BENZOATO ESTA CARACTERIZADA POR UN PATRON DE DIFRACCION EN POLVO DE RAYOS-X CON PICOS A APROXIMADAMENTE 3.7, 7.5, 18.7, 19.8, 15.2, 19.4, 19.9, 6.0 Y 21.9 GRADOS 2-THETA; LA SAL DE SUCCINATO ESTA CARACTERIZADA POR UN PATRON DE DIFRACCION EN POLVO DE RAYOS-X CON PICOS A APROXIMADAMENTE3.2, 19.8, 20.7, 23.3, 26.2, 9.8, 19.4, 24.5, 33.4, 26.6 Y 22.6 GRADOS 2-THETA. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHA SAL SE ENCUENTRA EN FORMA CRISTALINA SUSTANCIALMENTE PURA SIENDO UTIL COMO INMUNOSUPRESOR EN EL TRATAMIENTO Y/O PREVENCION DE ENFERMEDADES AUTOINMUNES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08168862 | 2008-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20120012A1 true PE20120012A1 (es) | 2012-02-02 |
Family
ID=42062355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011000987A PE20120012A1 (es) | 2008-11-11 | 2009-11-10 | Sales de fingolimod |
Country Status (20)
Country | Link |
---|---|
US (2) | US8680146B2 (es) |
EP (1) | EP2358660A2 (es) |
JP (2) | JP2012508215A (es) |
KR (1) | KR20110086142A (es) |
CN (2) | CN105198760A (es) |
AU (1) | AU2009315735B2 (es) |
BR (1) | BRPI0921533A2 (es) |
CA (1) | CA2741974A1 (es) |
CL (1) | CL2011001041A1 (es) |
CO (1) | CO6382154A2 (es) |
EC (1) | ECSP11011121A (es) |
IL (1) | IL212073A0 (es) |
MA (1) | MA32877B1 (es) |
MX (1) | MX2011004924A (es) |
NZ (1) | NZ591999A (es) |
PE (1) | PE20120012A1 (es) |
RU (1) | RU2543621C2 (es) |
TN (1) | TN2011000187A1 (es) |
WO (1) | WO2010055027A2 (es) |
ZA (1) | ZA201102272B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8940764B2 (en) | 2005-05-26 | 2015-01-27 | Aldexa Therapeutics, Inc. | Compositions and methods of treating retinal disease |
NZ591999A (en) * | 2008-11-11 | 2013-06-28 | Novartis Ag | Salts of fingolimod fty720 |
KR20120032538A (ko) | 2009-07-24 | 2012-04-05 | 라티오팜 게엠베하 | 핀골리모드 염의 제조 방법 |
MX2013004649A (es) | 2010-10-28 | 2013-06-05 | Mapi Pharma Ltd | Compuestos intermedios y proceso para la preparacion de fingolimod. |
WO2012071524A1 (en) | 2010-11-24 | 2012-05-31 | Ratiopharm Gmbh | Arylsulfonate salts of fingolimod and processes for preparation thereof |
AR085749A1 (es) | 2011-04-01 | 2013-10-23 | Novartis Ag | Formulaciones |
EP2505589A1 (en) | 2011-04-01 | 2012-10-03 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Novel sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof |
CN102887829B (zh) * | 2012-09-05 | 2014-07-02 | 中国科学院上海药物研究所 | 芬戈莫德粘酸盐及其晶体的制备方法和用途 |
ES2964891T3 (es) | 2013-03-05 | 2024-04-10 | Biocon Ltd | Un proceso para la preparación de compuestos de 2-amino-1,3-propanodiol y sales de los mismos |
US10022340B2 (en) | 2013-10-11 | 2018-07-17 | Teikoku Pharma Usa, Inc. | Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same |
US10675254B2 (en) | 2013-10-11 | 2020-06-09 | Teikoku Seiyaku Co., Ltd. | Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same |
US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
CA3022665A1 (en) | 2016-05-09 | 2017-11-16 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
DK3466934T3 (da) | 2016-05-31 | 2024-04-15 | Taiho Pharmaceutical Co Ltd | Sulfonamidforbindelser eller salt deraf som ribonukleotidreductase-inhibitorer til behandling af kræft |
RU2627691C1 (ru) * | 2016-07-06 | 2017-08-10 | Олег Ростиславович Михайлов | Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе |
CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
SG11202012787PA (en) * | 2018-06-29 | 2021-01-28 | Forma Therapeutics Inc | Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof |
CN112714762A (zh) * | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
CA3156298A1 (en) | 2019-10-31 | 2021-05-06 | Laetitia POUZOL | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
EP4353709A1 (en) * | 2021-05-31 | 2024-04-17 | Shanghai Yonsun Biotechnology Co., Ltd. | Pharmaceutical salt of fingolimod, preparation method therefor, pharmaceutical composition containing same and use thereof |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0627406B1 (en) | 1992-10-21 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
ECSP951461A (es) | 1995-06-07 | 1998-04-07 | SINTESIS DE 3- {4-(2- AMINOETOXI) BENZOIL]-2-ARIL-6- HIDROXIBENZO {b] TIOFENOS (CASO X- 9295B) | |
ECSP972265A (es) | 1997-09-23 | 1998-11-30 | Dihidrato de d-olanzapina | |
FR2785607B1 (fr) | 1998-11-09 | 2001-02-09 | Rhodia Chimie Sa | Procede de preparation de tris(ether-amine) |
EP1457478B1 (en) * | 1998-11-11 | 2017-07-19 | Novartis AG | Production of 2-amino-2-[2-(4-alkyl-phenyl)ethyl]propane-1,3-diols |
JP4627356B2 (ja) * | 1999-06-30 | 2011-02-09 | 松森 昭 | ウイルス性心筋炎の予防または治療薬剤 |
JP4476623B2 (ja) * | 2001-06-08 | 2010-06-09 | ノバルティス アーゲー | インスリン産生細胞移植片拒絶の処置または予防 |
EP1944026B1 (en) * | 2002-05-16 | 2013-06-26 | Novartis AG | Use of EDG receptor binding agents in cancer |
GB0217152D0 (en) * | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
KR20050121712A (ko) | 2003-04-08 | 2005-12-27 | 노파르티스 아게 | 유기 화합물 |
PL1828160T3 (pl) * | 2004-12-21 | 2012-02-29 | Merck Serono Sa | Cykliczne pochodne sulfonyloaminowe i ich zastosowanie |
GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
US20080221200A1 (en) * | 2005-09-30 | 2008-09-11 | Malcolm Allison | Combination of Organic Compounds |
US8318812B2 (en) * | 2006-06-02 | 2012-11-27 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of lymphoid malignancies |
WO2009100116A1 (en) * | 2008-02-04 | 2009-08-13 | Medical College Of Georgia Research Institute | Oligodendrocyte precursor cell composition and methods of use |
NZ591999A (en) * | 2008-11-11 | 2013-06-28 | Novartis Ag | Salts of fingolimod fty720 |
-
2009
- 2009-11-10 NZ NZ591999A patent/NZ591999A/xx not_active IP Right Cessation
- 2009-11-10 JP JP2011535129A patent/JP2012508215A/ja not_active Withdrawn
- 2009-11-10 US US13/128,832 patent/US8680146B2/en not_active Expired - Fee Related
- 2009-11-10 CA CA2741974A patent/CA2741974A1/en not_active Abandoned
- 2009-11-10 BR BRPI0921533A patent/BRPI0921533A2/pt not_active IP Right Cessation
- 2009-11-10 CN CN201510547567.5A patent/CN105198760A/zh active Pending
- 2009-11-10 AU AU2009315735A patent/AU2009315735B2/en not_active Ceased
- 2009-11-10 CN CN2009801448205A patent/CN102256933A/zh active Pending
- 2009-11-10 EP EP09752168A patent/EP2358660A2/en not_active Withdrawn
- 2009-11-10 MX MX2011004924A patent/MX2011004924A/es active IP Right Grant
- 2009-11-10 PE PE2011000987A patent/PE20120012A1/es not_active Application Discontinuation
- 2009-11-10 WO PCT/EP2009/064889 patent/WO2010055027A2/en active Application Filing
- 2009-11-10 KR KR1020117013304A patent/KR20110086142A/ko not_active Application Discontinuation
- 2009-11-10 RU RU2011123365/04A patent/RU2543621C2/ru not_active IP Right Cessation
-
2011
- 2011-03-28 ZA ZA2011/02272A patent/ZA201102272B/en unknown
- 2011-03-31 IL IL212073A patent/IL212073A0/en unknown
- 2011-04-19 TN TN2011000187A patent/TN2011000187A1/fr unknown
- 2011-05-10 CL CL2011001041A patent/CL2011001041A1/es unknown
- 2011-05-12 CO CO11058592A patent/CO6382154A2/es not_active Application Discontinuation
- 2011-06-03 MA MA33910A patent/MA32877B1/fr unknown
- 2011-06-10 EC EC2011011121A patent/ECSP11011121A/es unknown
-
2014
- 2014-02-13 US US14/179,807 patent/US20140235722A1/en not_active Abandoned
-
2015
- 2015-04-24 JP JP2015089480A patent/JP2015178503A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2010055027A3 (en) | 2010-08-19 |
EP2358660A2 (en) | 2011-08-24 |
CO6382154A2 (es) | 2012-02-15 |
ECSP11011121A (es) | 2011-07-29 |
AU2009315735B2 (en) | 2013-01-10 |
US20140235722A1 (en) | 2014-08-21 |
CN105198760A (zh) | 2015-12-30 |
KR20110086142A (ko) | 2011-07-27 |
RU2543621C2 (ru) | 2015-03-10 |
JP2015178503A (ja) | 2015-10-08 |
CA2741974A1 (en) | 2010-05-20 |
AU2009315735A1 (en) | 2010-05-20 |
NZ591999A (en) | 2013-06-28 |
MA32877B1 (fr) | 2011-12-01 |
WO2010055027A2 (en) | 2010-05-20 |
CL2011001041A1 (es) | 2011-10-07 |
MX2011004924A (es) | 2011-05-30 |
ZA201102272B (en) | 2011-12-28 |
JP2012508215A (ja) | 2012-04-05 |
CN102256933A (zh) | 2011-11-23 |
BRPI0921533A2 (pt) | 2016-01-12 |
US8680146B2 (en) | 2014-03-25 |
TN2011000187A1 (en) | 2012-12-17 |
IL212073A0 (en) | 2011-06-30 |
RU2011123365A (ru) | 2012-12-20 |
US20110218248A1 (en) | 2011-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20120012A1 (es) | Sales de fingolimod | |
CY1124208T1 (el) | Αλατα η συγκρυσταλλοι της 3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης | |
JP2013525444A5 (es) | ||
RU2015111229A (ru) | Кристаллические формы гидрохлорида финголимода | |
DOP2014000064A (es) | Compuestos 1-arilcarbonil-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas | |
CL2014003475A1 (es) | Forma c cristalina de acido obeticolico; proceso de preparacion de la forma 1 de acido obeticolico a partir de la forma c cristalina; composicion farmaceutica que comprende a una forma cristalina de acido obeticolico, util para el tratamiento o prevencion de una enfermedad hepatica colestasica, hepatopatia alcoholica y enfermedades cardiovasculares tal como aterosclerosis, entre otras. | |
PE20120989A1 (es) | Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo | |
BR112014005389A8 (pt) | Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal | |
CL2012003009A1 (es) | Acido3-(((3-butil-3-etil-(metiloxi)-1-1-dioxido-5-fenil-2,3,4,5-tetrahidro-1,4benxotiazepin-8-il)-metil)-amino)-pentanodioco; composicion farmaceutica que lo comprende; y su uso en un tastorno metabolico. pct. | |
PE20141539A1 (es) | Una nueva composicion terapeutica que contiene apomorfina como principio activo | |
UY32030A (es) | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" | |
UY33317A (es) | Nuevos derivados de pirazol | |
ECSP12012125A (es) | Ariltriazolonas ligadas a bisarilo y su uso | |
AR082640A1 (es) | Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada | |
CL2014000441A1 (es) | Una entidad quimica que comprende el compuesto sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo; inhibidor de la activacion de la enzima nedd-8; forma cristalina i; profarmaco del compuesto; composicion farmaceutica; un metodo para tratar el cancer. | |
PE20140337A1 (es) | Nuevas formas cristalinas de la sal sodica del acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclhexil)-acetico | |
PE20141113A1 (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
NZ601920A (en) | New crystalline form of a cyclopropyl benzamide derivative | |
CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
JP2013521297A5 (es) | ||
PE20081797A1 (es) | Nueva forma de dosificacion | |
AR074592A1 (es) | Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina, procesos e intermediario para su sintesis y su uso en el tratamiento de una enfermedad mediada por un antagonista de los receptores mu opioides. | |
AR080150A1 (es) | Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento del trastorno obsesivo compulsivo (toc) | |
AR064215A1 (es) | Proceso para obtener el r-enantiomero de salbutamol | |
ECSP088088A (es) | Maleato de 3-[2-(dimetilamino)metil-(ciclohex-1-il)]fenol y sus formas cristalinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |